ACR appropriateness criteria® definitive therapy for early-stage cervical cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 4, 2012, Pages 399-405

  Small, William ^a   Strauss, Jonathan B ^a   Jhingran, Anuja ^b   Yashar, Catheryn M ^c   Cardenes, Higinia R ^f   Erickson Wittmann, Beth A ^h   Gullett, Norleena ^f   Kidd, Elizabeth ^d   Lee, Larissa J ⁱ   Mayr, Nina A ^j   Moore, David ^g,q   Puthawala, Ajmel A ^e   Rao, Gautam G ^l,r   Varia, Mahesh A ^m   Wahl, Andrew O ⁿ   Wolfson, Aaron H ^o   Yuh, William ^k   Gaffney, David K ^p  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^f INDIANA UNIVERSITY   (United States)

^g INDIANA UNIVERSITY   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^l UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^o UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^q American College of Obstetricians and Gynecologists   (United States)

^r AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

more..

Author keywords

ACR; Appropriateness criteria; cancer; cervix; radiotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; PACLITAXEL;

AMERICAN COLLEGE OF RADIOLOGY APPROPRIATENESS CRITERIA; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; EARLY CANCER; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYSTERECTOMY; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POST TREATMENT SURVIVAL; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

EID: 84864339451     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182610537     Document Type: Review

References (62)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. A Cancer J Clin. 2011;61:69-90.
2. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105: 107-108.
3. American College of Radiology. ACR Appropriateness Criterias: Pretreatment planning of invasive cancer of the cervix. Available at: Http://www.acr.org/SecondaryMainMenuCategories/quality-safety/app-criteria/pdf/ ExpertPanelonWomensImaging/Invasive CanceroftheCervixDoc5.aspx. Accessed March 1, 2012.
4. Kim SH, Choi BI, Lee HP, et al. Uterine cervical carcinoma: Comparison of CT and MR findings. Radiology. 1990;175:45-51.
5. Bellomi M, Bonomo G, Landoni F, et al. Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma. Eur Radiol. 2005;15:2469-2474. (Pubitemid 43153848)
6. Mitchell DG, Snyder B, Coakley F, et al. Early invasive cervical cancer: Tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol. 2006;24:5687-5694. (Pubitemid 46631310)
7. Choi HJ, Roh JW, Seo SS, et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/ computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: A prospective study. Cancer. 2006;106:914-922. (Pubitemid 43238460)
8. Boughanim M, Leboulleux S, Rey A, et al. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol. 2008;26:2558-2561.
9. Leblanc E, Gauthier H, Querleu D, et al. Accuracy of 18-fluoro- 2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma. Ann Surg Oncol. 2011;18:2302-2309.
10. Gold MA, Tian C, Whitney CW, et al. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: A Gynecologic Oncology Group Study. Cancer. 2008;112: 1954-1963. (Pubitemid 351574071)
11. Hasenburg A, Salama JK, Van TJ, et al. Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer. Gynecol Oncol. 2002;84: 321-326. (Pubitemid 34136787)
12. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350:535-540. (Pubitemid 27348428)
13. Eifel PJ, Moughan J, Erickson B, et al. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: A patterns of care study. Int J Radiat Oncol Biol Phys. 2004;60: 1144-1153. (Pubitemid 39440800)
14. Erickson B, Eifel P, Moughan J, et al. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): A patterns of care study. Int J Radiat Oncol Biol Phys. 2005;63: 1083-1092. (Pubitemid 41505287)
15. Barillot I, Horiot JC, Cuisenier J, et al. Carcinoma of the cervical stump: A review of 213 cases. Eur J Cancer. 1993;29A: 1231-1236. (Pubitemid 23169887)
16. Lanciano RM, Won M, Coia LR, et al. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: A final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys. 1991;20:667-676.
17. Mell LK, Tiryaki H, Ahn KH, et al. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:1504-1510. (Pubitemid 351978176)
18. Portelance L, Chao KS, Grigsby PW, et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001;51: 261-266. (Pubitemid 32758886)
19. Hasselle MD, Rose BS, Kochanski JD, et al. Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2011;80:1436-1445.
20. Beadle BM, Jhingran A, Salehpour M, et al. Cervix regression and motion during the course of external beam chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys. 2009;73:235-241.
21. Chan P, Dinniwell R, Haider MA, et al. Inter- and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: A cinematic-MRI point-of-interest study. Int J Radiat Oncol Biol Phys. 2008;70:1507-1515.
22. Adli M, Mayr NA, Kaiser HS, et al. Does prone positioning reduce small bowel dose in pelvic radiation with intensity-modulated radiotherapy for gynecologic cancer? Int J Radiat Oncol Biol Phys. 2003;57:230-238. (Pubitemid 36959761)
23. Ahmad R, Hoogeman MS, Bondar M, et al. Increasing treatment accuracy for cervical cancer patients using correlations between bladder-filling change and cervix-uterus displacements: Proof of principle. Radiother Oncol. 2011;98:340-346.
24. American College of Radiology. ACR Appropriateness Criterias: Role of adjuvant therapy in the management of early stage cervical cancer. Available at: Http://www.acr.org/SecondaryMainMenuCa tegories/quality-safety/app-criteria/ pdf/RO-Gyn/Early-Stage-Cervical- Cancer.aspx. Accessed March 1, 2012.
25. Higginson DS, Morris DE, Jones EL, et al. Stereotactic body radiotherapy (SBRT): Technological innovation and application in gynecologic oncology. Gynecol Oncol. 2011;120:404-412.
26. Mayr NA, Huang Z, Sohn JW, et al. Emerging application of stereotactic body radiation therapy for gynecologic malignancies. Expert Rev Anticancer Ther. 2011;11:1071-1077.
27. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22: 872-880. (Pubitemid 41103599)
28. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161. (Pubitemid 29177874)
29. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966-972. (Pubitemid 34141839)
30. Roberts KB, Urdaneta N, Vera R, et al. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer. 2000;90:206-223.
31. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: Individual patient data meta-analysis. Cochrane Database Syst Rev. 2010;CD008285.
32. Gaffney DK, Du Bois A, Narayan K, et al. Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys. 2007;68:485-490. (Pubitemid 46711149)
33. Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: Results from the Italian multicenter randomized study. J Clin Oncol. 2002;20: 179-188. (Pubitemid 34032610)
34. Chang TC, Lai CH, Hong JH, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol. 2000;18:1740-1747.
35. Choi YS, Sin JI, Kim JH, et al. Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer. J Korean Med Sci. 2006;21:683-689. (Pubitemid 44199324)
36. Neoadjuvant chemotherapy for locally advanced cervical cancer: A systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39: 2470-2486.
37. Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2010;CD007406.
38. Monk BJ, Koh WJ. What is the standard therapy for bulky stage IB cervical cancer? Int J Gynecol Cancer. 2009;19:480.
39. Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA. 1995;274:387-393.
40. Grigsby PW, Heydon K, Mutch DG, et al. Long-term follow-up of RTOG 92-10: Cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001;51:982-987. (Pubitemid 33026428)
41. Small W Jr., Winter K, Levenback C, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: Results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007;68:1081-1087. (Pubitemid 47048563)
42. Beadle BM, Jhingran A, Yom SS, et al. Patterns of regional recurrence after definitive radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2010;76:1396-1403.
43. Keys HM, Bundy BN, Stehman FB, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: A randomized trial of the Gynecologic Oncology Group. Gynecol Oncol. 2003;89:343-353. (Pubitemid 36687776)
44. Stehman FB, Ali S, Keys HM, et al. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: Follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007;197:e501-e506, 503.
45. Nijhuis ER, van der Zee AG, in't Hout BA, et al. Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys. 2006;66:699-705. (Pubitemid 44436692)
46. Schwarz JK, Siegel BA, Dehdashti F, et al. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007;298:2289-2295. (Pubitemid 350146219)
47. Wang JZ, Mayr NA, Zhang D, et al. Sequential magnetic resonance imaging of cervical cancer: The predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy. Cancer. 2010;116:5093-5101.
48. Huang YT, Wang CC, Tsai CS, et al. Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2011;80:429-436.
49. Lea JS, Coleman RL, Garner EO, et al. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol. 2003;91:558-562. (Pubitemid 38388150)
50. Duenas-Gonzalez A, Zarba JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29: 1678-1685.
51. Winter WE 3rd, Maxwell GL, Tian C, et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: A Gynecologic Oncology Group Study. Gynecol Oncol. 2004;94:495-501. (Pubitemid 39024559)
52. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528-1536. (Pubitemid 29489787)
53. Mayr NA, Wang JZ, Zhang D, et al. Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer. Int J Radiat Oncol Biol Phys. 2009;74: 1513-1521.
54. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108:317-325.
55. Potter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67-77. (Pubitemid 43131038)
56. Dimopoulos JC, Potter R, Lang S, et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance imageguided brachytherapy. Radiother Oncol. 2009;93:311-315.
57. Engle DB, Bradley KA, Chappell RJ, et al. The effect of laparoscopic guidance on gynecologic interstitial brachytherapy. J Minim Invasive Gynecol. 2008;15:541-546.
58. Shah AP, Strauss JB, Gielda BT, et al. Toxicity associated with bowel or bladder puncture during gynecologic interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2010;77:171-179.
59. Viani GA, Manta GB, Stefano EJ, et al. Brachytherapy for cervix cancer: Low-dose rate or high-dose rate brachytherapy-a metaanalysis of clinical trials. J Exp Clin Cancer Res. 2009;28:47.
60. Jones ND, Rankin J, Gaffney DK. Is simulation necessary for each high-dose-rate tandem and ovoid insertion in carcinoma of the cervix? Brachytherapy. 2004;3:120-124. (Pubitemid 39472675)
61. Perez CA, Grigsby PW, Castro-Vita H, et al. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1995;32:1275-1288.
62. Petereit DG, Sarkaria JN, Chappell R, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys. 1995;32:1301-1307.